ElevateBio is seeking out partnerships for its lead gene therapy after the construct reduced the levels of a toxic protein in ...

The molecular glue wave that first began years ago is still swelling, with Eli Lilly earmarking approximately $1.25 billion ...

Adagio will now put its resources toward completing the pivotal U.S. trial of its vCLAS catheter and its subsequent marketing ...

For a while, special purpose acquisition companies were biotech’s hot ticket to the public markets. | For a while, special ...

Praxis Precision Medicines has been blindsided by a recommendation to stop a phase 3 essential tremor trial. Two months after ...

Vir Biotechnology may be pushing ahead with its combination therapy in hepatitis D, but it's pausing further development in ...

Kallyope has slipped out results from a phase 2 trial of its obesity candidates, linking the combination of the two oral ...

When Silence Therapeutics unveiled its latest zerlasiran phase 2 data at the American Heart Association (AHA) conference in ...

The Department of Health and Human Services is re-evaluating a $590 million contract for avian influenza mRNA vaccines that ...

Gene therapy maker bluebird bio’s 15-year flight has landed in the nest of private equity firms Carlyle and SK Capital in a ...

Even as President Donald Trump wages a very public fight against diversity, equity and inclusion (DEI) initiatives in the ...

AbbVie-partnered Mission Therapeutics is tweaking its trajectory, closing a preclinical laboratory in the U.K. to focus on ...